Medical Voice 20th December 2019 |
News and Updates
eMediNexus Coverage from: 
Medical Voice 20th December 2019

0 Read Comments                

SPARC signs pact with Bioprojet to acquire exclusive rights for drug to treat auto-immune diseases

SPARC and Bioprojet co-owned all SCD-044 related IP, developed through a research collaboration targeting Sphingosine-1-Phosphate Receptors to treat various autoimmune disorders.

New Delh: Sun Pharma Advanced Research Company (SPARC) on Thursday said that it has entered a pact with Bioprojet SCR (Bioprojet) to acquire exclusive rights for investigational medicinal product SCD-044, SCD-044 which is a novel investigational oral product, under development for the treatment of auto-immune diseases. Phase I studies for SCD-044 have been completed, SPARC said in a filing to BSE.

"SPARC... announced that it has entered into an agreement with Bioprojet SCR (Bioprojet) to exclusively acquire Bioprojets rights to the investigational medicinal product SCD-044," the company said. more

Standard Treatment of Diabetic Nephropathy (eGFR >30): ACE Inhibitor OR AR Blocker PLUS SGLT-2 Inhibitor

Diabetic nephropathy or overt proteinuria (macroalbuminuria, or "severely increased albuminuria") is usually present with worse glycemic control, hypertension, glomerular hyperfiltration, or in patients with a genetic predisposition.

The earliest clinical manifestation of renal involvement in diabetes is an increase in albumin excretion (microalbuminuria, or "moderately increased albuminuria").

Glycemic control can partially reverse the glomerular hypertrophy and hyperfiltration, delay the development of elevated albumin excretion, stabilize or decrease protein excretion in patients with increased albumin excretion, and can slow the progression of glomerular filtration rate decline. more

Most Popular Videos

Dental Health and Its Impact on General Health

Healthcare News Monitor


NPPA drug price hike a limited positive, say pharma players

Business Today- E Kumar Sharma

Drug price controls are in the spotlight. Leading pharma units heave a sigh of relief that the government has, arguably for the first time, invoked para 19 provisions of the Drug Prices Control Order, 2013 for an upward revision in drug prices. Industry watchers, however, say that it may lead to some pharma players opting more for medicines not falling under the drug price control regime. Notably, the National Pharmaceutical Pricing Authority (NPPA) has increased the ceiling prices of 21 formulations by 50 per cent. Industry players say the move augurs well as it indicates the government is being receptive to the needs of pharma industry. "This is a positive move and is a sign of the governments willingness to consider genuine demands of the industry and a recognition of the fact that access is a function of both affordability and viability," says Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA). "It was needed in the light of the rising API and overall manufacturing costs that the industry was grappling with," he adds. Nevertheless, for some, the move is a "limited positive" since the announcement does not indicate if more products will be considered for the price hike in due course. While a 50 per cent jump, in an absolute term, seems big, it is not much if compared against the rise in the manufacturing cost.

Indian pharma sector expected to grow at 10-12 per cent during FY19-22, outlook stable: ICRA

The New Indian Express- PTI

Ratings agency Icra on Wednesday said the Indian pharmaceutical industry is expected to grow around 10-12 per cent between FY2019 and FY2022 while maintaining a stable outlook on the sector. Icra cited abating headwinds from pricing pressure in the US (which is the largest regulated market), stable growth for the Indian market driven by increasing healthcare spending and better accessibility as likely key growth drivers for the Indian pharma companies, coupled with comfortable balance sheet structure. It, however, said increased cost related to regulatory compliances, especially for the US market, price controls across markets and mandatory genericisation for the Indian market remained key risks. "The domestic pharmaceutical industry has gained adequate scale and generic drug development capabilities over a decade of growth which will keep them in good stead to capture bigger opportunities, especially in the specialty/niche segments in the regulated market," Icra said in a statement.

Latecomer doctor refuses to treat elderly


Kolkata: A doctor from private hospital in Dhakuria wrote on a patients prescription that he would not attend the patient in future and urged the hospital authorities to refund the fees taken from him and not to fix any appoint for the patient. The incident triggered a sense of shock among various sections people in the city as to how a doctor whose primary job is to provide treatment to the patients can single out a patient and write on his prescription that he would not treat the patient. A 68-year-old man had been suffering from kidney related problems and had undergone a dialysis at this hospital a number of times in the past. He was asked to appear in the hospital on Tuesday. The family members of the patient had a prior appointment at the hospital. They alleged that the elderly man had to wait for a long time as the doctor did not come on time. They said as the patient started having pain in his leg due to some other health ailments, they urged the staff members of the hospital to call up the doctor as further delay in his dialysis would put him in trouble. The staff members advised the patients relatives to wait for sometime. When the doctor finally arrived he called the patient and wrote on his prescription that this patient should not be given appointment in future. The doctor also urged the hospital authorities that the fees of the patient must be refunded as the "time of appointment was delayed". The patients daughter said how a doctor can refuse to treat a patient. She asked why the doctor took such a drastic step. A senior official of the hospital said that they fix appointments on the basis of what the doctors say. "The doctor came late but we extended all our cooperation to the patient and his family members," the official said. The official further said: "We had no hand in fixing the time of the appointment. It was fixed at a time suggested by him (the doctor). The hospital will take action against him."

Government Rajaji Hospital: Female PG doctor assaulted by patient kin; Doctors stage flash protest

Medical Dialogues

A 31-year-old female PG doctor attached to Government Rajaji Hospital (GRH) was assaulted by the kin of a patient, after being asked to take off their shoes before entering the sterile ward. The attack triggered the fellow doctors and nurses, who boycotted OPD services and staged a flash protest demanding an FIR against the two suspects under non-bailable provisions of the Tamil Nadu Hospital Protection (TNHP) Act, 2008. Madhurai: The incident took place on December 14 (Saturday) when a (PG) student doctor, who was on duty at the Labour Theatre (LT) II in the Comprehensive Emergency Obstetric and Newborn Care (CEmONC) block of GRH, asked two women, to remove her footwear before entering the sterile ward. The instruction did not go down well with the duo, who had visited there to attend a woman admitted for delivery and they allegedly charged the doctor physically and assaulted her. Soon after, the victimized doctor moved a complaint with the GRH police. The women were booked under Sections 294 (b) (punishment for uttering obscene words), 332 (punishment for voluntarily causing hurt to deter public servant from duty), 353 (punishment for assaulting a public servant), 355 (punishment for assaulting with intent to dishonour a person) of the Indian Penal Code, and under the TNHP Act.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now